CSL

CSL Behring to acquire Calimmune for $91M

Monday, August 28, 2017

Global biotherapeutics provider CSL Behring has agreed to acquire Calimmune, a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D facilities in Pasadena, California, and Sydney, Australia, for an upfront payment of $91 million. 

[Read More]

CSL Behring receives Orphan Drug exclusivity for Haegarda

Monday, July 24, 2017

CSL Behring announced that the FDA has granted the company seven years of orphan drug exclusivity for Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment option for prevention of hereditary angioedema (HAE) attacks. Haegarda was approved by the FDA on June 22, 2017 for routine prophylaxis to prevent HAE attacks in adolescent and adult patients, and marketing exclusivity will continue through June 22, 2024.

[Read More]

FDA approves CSL Behring’s AFSTYLA for hemophilia A

Tuesday, May 31, 2016

CSL Behring has announced that the FDA has approved AFSTYLA [Antihemophilic Factor (Recombinant), Single Chain], its novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A. AFSTYLA is the first and only single-chain product for hemophilia A that is specifically designed for long-lasting protection from bleeds with two to three times weekly dosing.

[Read More]

GSK, Novartis complete major three-part transaction

Monday, March 2, 2015

GlaxoSmithKline and Novartis have completed their three-part transaction. As a result, GSK has acquired Novartis’ global vaccines business (excluding influenza vaccines) for $5.25 billion and has divested its oncology business to Novartis for $16 billion. In addition, the two have created a new consumer healthcare joint venture in which GSK will have majority control and an equity interest of 63.5%.

[Read More]

ALK, bioCSL partner for allergy tablets

Wednesday, February 11, 2015

ALK and bioCSL have entered into a long-term partnership covering three ALK products in Australia and New Zealand. The agreement grants bioCSL exclusive rights in Australia and New Zealand to ALK’s sublingual allergy immunotherapy tablets (SLIT-tablets) for house dust mite (HDM) allergy and grass pollen allergy (marketed as Grazax in Europe and Grastek in North America), and its adrenaline auto-injector, Jext. ALK will be responsible for product supply and bioCSL will undertake registration and commercialization of the products.

[Read More]

CSL Behring expands manufacturing capabilities

Thursday, October 9, 2014

CSL Behring, a King of Prussia, Pa.-based provider of plasma protein therapeutics, has announced a multi-year, $450-million two-site global capacity expansion, the latest in a series of recent production expansions to meet the growing need for therapies used to treat patients with rare and serious medical disorders around the world. 

[Read More]

ASLAN Pharmaceuticals, CSL ink agreement for asthma

Wednesday, May 14, 2014

ASLAN Pharmaceuticals, a specialty pharmaceutical company developing novel medicines for global markets, with offices in Singapore and Taiwan, has announced a global license agreement to develop CSL anti-IL13 receptor monoclonal antibody, CSL334, currently in preclinical development for the treatment of asthma. CSL Limited is a global biopharmaceutical company headquartered in Melbourne, Australia that develops, manufactures and markets biotherapies to prevent and treat serious human diseases.

[Read More]